Switch theme
Sign up to access all valuation multiples
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
2001
103
LTM Revenue $1.3M
LTM EBITDA -$24.5M
$102M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AB Science has a last 12-month revenue (LTM) of $1.3M and a last 12-month EBITDA of -$24.5M.
In the most recent fiscal year, AB Science achieved revenue of $1.2M and an EBITDA of -$5.5M.
AB Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AB Science valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | XXX | $1.2M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | $1.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 116% | XXX | XXX | XXX |
| EBITDA | -$24.5M | XXX | -$5.5M | XXX | XXX | XXX |
| EBITDA Margin | -1894% | XXX | -459% | XXX | XXX | XXX |
| EBIT | -$24.5M | XXX | -$6.8M | XXX | XXX | XXX |
| EBIT Margin | -1896% | XXX | -567% | XXX | XXX | XXX |
| Net Profit | -$24.8M | XXX | -$8.8M | XXX | XXX | XXX |
| Net Margin | -1922% | XXX | -731% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AB Science's stock price is EUR 1 (or $1).
AB Science has current market cap of EUR 80.2M (or $90.1M), and EV of EUR 90.7M (or $102M).
See AB Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $90.1M | XXX | XXX | XXX | XXX | $-0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AB Science has market cap of $90.1M and EV of $102M.
AB Science's trades at 84.6x EV/Revenue multiple, and -18.4x EV/EBITDA.
Equity research analysts estimate AB Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AB Science has a P/E ratio of -3.6x.
See valuation multiples for AB Science and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $90.1M | XXX | $90.1M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | 78.9x | XXX | 84.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.2x | XXX | -18.4x | XXX | XXX | XXX |
| EV/EBIT | -4.2x | XXX | -14.9x | XXX | XXX | XXX |
| EV/Gross Profit | 78.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.6x | XXX | -10.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 245.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAB Science's last 12 month revenue growth is 10%
AB Science's revenue per employee in the last FY averaged $12K, while opex per employee averaged $0.1M for the same period.
AB Science's rule of 40 is -531% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AB Science's rule of X is -1869% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AB Science and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | -1894% | XXX | -459% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -531% | XXX | -449% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1869% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $12K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 367% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 684% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AB Science acquired XXX companies to date.
Last acquisition by AB Science was XXXXXXXX, XXXXX XXXXX XXXXXX . AB Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AB Science founded? | AB Science was founded in 2001. |
| Where is AB Science headquartered? | AB Science is headquartered in France. |
| How many employees does AB Science have? | As of today, AB Science has 103 employees. |
| Who is the CEO of AB Science? | AB Science's CEO is Mr. Alain Moussy. |
| Is AB Science publicy listed? | Yes, AB Science is a public company listed on PAR. |
| What is the stock symbol of AB Science? | AB Science trades under AB ticker. |
| When did AB Science go public? | AB Science went public in 2010. |
| Who are competitors of AB Science? | Similar companies to AB Science include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AB Science? | AB Science's current market cap is $90.1M |
| What is the current revenue of AB Science? | AB Science's last 12 months revenue is $1.3M. |
| What is the current revenue growth of AB Science? | AB Science revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of AB Science? | Current revenue multiple of AB Science is 78.9x. |
| Is AB Science profitable? | Yes, AB Science is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AB Science? | AB Science's last 12 months EBITDA is -$24.5M. |
| What is AB Science's EBITDA margin? | AB Science's last 12 months EBITDA margin is -1894%. |
| What is the current EV/EBITDA multiple of AB Science? | Current EBITDA multiple of AB Science is -4.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
